U.S. Markets closed

3 Big Drug-Distributor Stocks Have Been Battered. Now They Look Like Bargains.

Josh Nathan-Kazis

Weak prices for generics, potential opioid liability, and rumbles of change coming from Washington pose challenges. But the market reaction has been overdone.